Dominik Huber
Dominik Huber, Our Head of Upstream Manufacturing in Vienna, Dominik Huber, has built his entire, senior-level career with Boehringer Ingelheim.
Search
Nelli Milosch
Nelli Milosch, a team lead for our field-based medical team in Germany, says that the people is the best thing about working in Boehringer Ingelheim.
Sites Around the World
Click here to view our biggest sites. With 52,000 employees worldwide, Boehringer Ingelheim has a research and production network across the globe.
Innovating for our business
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Diabetes
Diabetes
Celebrating the power of people and their experiences: Observations for Hispanic/ Latinx Heritage Month
Our Boehringer colleagues share how their experiences with their culture have influenced their approach to life and work.
Family owned
Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
New Documentary Highlights Ranch’s Commitment to Cattle Health
New Documentary Highlights Ranch’s Commitment to Cattle Health
Expanded Access Programs
Expanded Access Programs
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)
Novel antibody shows potential to transform treatment of rare form of psoriasis
Novel antibody shows potential to transform treatment of rare form of psoriasis
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Yankees Baseball Legend Bernie Williams Raises Awareness of Devastating Lung Disease – IPF – in Honor of his Dad
Yankees Baseball Legend Bernie Williams Raises Awareness Of Devastating Lung Disease – Ipf – In Honor Of His Dad
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD
FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD
New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies
New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
Investigational Compound Granted FDA Orphan Drug Designation
U.S. FDA Grants Orphan Drug Designation to Investigational Compound for Idiopathic Pulmonary Fibrosis
Express Scripts Adds BI Products to Roster | BI US
Read more on Express Scripts adding the Spiriva Respimat, Spiriva Handihaler and Stiolto Respimat to their commercial national preferred formulary.
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Corporate Compliance Program
Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations
U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children